Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Sir_Holleron Jun 18, 2015 1:05pm
93 Views
Post# 23844692

RE:RE:Well proven

RE:RE:Well provenBTI provided an update since that post on April 10. Where have you been. Even Rob said an update was overdue. While it looked like Herceptin may have been on a backburner in the last MD&A we were informed of testing that had gone on off the record. The anti-tumor activity with Transcendpep was superior to previous testing and with all the data in hand the Directors wanted to move ahead with human testing. Survival data was talked about saying statistically significant survival was observed.

Concerning Lysosomal Storage Disease, with the live animal testing complete, and liver analysis data in hand, Rob anticipated ``pretty exciting, fantastic`data in the near term. Sounds like the animals appear to have done alright. Transcendpep appear to be working based upon liver analysis. 

Concerning where Medimmune went, their program was talked about with superior results reported. The half-life issue was addressed answering important questions of pharma according to Rob. In the video Medimmune`s work was said to be continuing and getting better every day.


Bullboard Posts